PRLD
NASDAQ · Biotechnology
Prelude Therapeutics Inc
$5.07
+0.24 (+4.97%)
Financial Highlights (FY 2026)
Revenue
13.44M
Net Income
-110,082,040
Gross Margin
—
Profit Margin
-819.6%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | 44.6% | 44.6% | 44.6% |
| Operating Margin | -861.3% | 2.4% | 2.2% | 2.0% |
| Profit Margin | -819.6% | 2.1% | 2.1% | 1.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 13.44M | 132.26M | 127.36M | 112.48M |
| Gross Profit | — | 59.02M | 56.83M | 50.19M |
| Operating Income | -115,725,241 | 3.13M | 2.80M | 2.22M |
| Net Income | -110,082,040 | 2.80M | 2.65M | 2.17M |
| Gross Margin | — | 44.6% | 44.6% | 44.6% |
| Operating Margin | -861.3% | 2.4% | 2.2% | 2.0% |
| Profit Margin | -819.6% | 2.1% | 2.1% | 1.9% |
| Rev Growth | — | +3.8% | -1.6% | +5.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 48.17M | 45.92M | 54.82M |
| Total Equity | — | 75.94M | 77.37M | 76.22M |
| D/E Ratio | — | 0.63 | 0.59 | 0.72 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -113,794,296 | 4.42M | 4.16M | 3.31M |
| Free Cash Flow | — | 2.17M | 2.21M | 2.87M |